Annotation Detail
Information
- Associated Genes
- PIK3CA
- Associated Variants
-
PIK3CA MUTATION
PIK3CA MUTATION - Associated Disease
- endometrial cancer
- Source Database
- CIViC Evidence
- Description
- 94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. No predictive biomarkers were identified, including PIK3CA mutations (N=21/73), KRAS mutations (10/73) or PTEN loss.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/892
- Gene URL
- https://civic.genome.wustl.edu/links/genes/37
- Variant URL
- https://civic.genome.wustl.edu/links/variants/311
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Endometrial Cancer
- Evidence Direction
- Does Not Support
- Drug
- Ridaforolimus,Temsirolimus
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24166148
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Ridaforolimus | Sensitivity | false |
| Temsirolimus | Sensitivity | false |